ERBB2 and breast cancer: The combination of trastuzumab (also known as Herceptin), a humanized monoclonal antibody (mAb) against the Her-2 receptor [7], and neoadjuvant chemotherapy has improved the response rate for breast cancers that overexpress Her-2.